TY  - JOUR
T1  - Long-Term Follow-Up Outcomes of Cervical Cancer Patients: A Single Center Experience from the East Anatolian Region of Turkey
TT  - Servikal Kanser Hastalarinin Uzun Dönem Sonuçlari: Doğu Anadolu Tek Merkez Deneyimi
AU  - Mirili, Cem
AU  - Yılmaz, Ali
AU  - Bilici, Mehmet
AU  - Basol Tekin, Salim
PY  - 2019
DA  - December
DO  - 10.5798/dicletip.579312
JF  - Dicle Medical Journal
JO  - diclemedj
PB  - Dicle Üniversitesi
WT  - DergiPark
SN  - 1300-2945
SP  - 857
EP  - 865
VL  - 46
IS  - 4
LA  - en
AB  - Objective: Cervical cancer (CC) is the 4th most common cause ofcancer-related deaths in women all over the world. The most important etiologiccause is HPV, and this allows tumor to have high chance of curing with earlydiagnosis by screening programs. However, information about long-term survivaldata of CC is limited in our country. In our study; we wanted to reveal the survivaltimes of our patients with CC and the factors that predict these times.Material and methods: Seventy-three patientswith CC, followed between2000 and 2017 were analyzed retrospectively.Associations between clinical and histopathological parameters with overallsurvival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier curves and compared by the log-rank test. Univariate and multivariateanalysis were used to assess their prognostic values for PFS and OS.Results: The median age of the patients was 56 years. The mostcommon histological subtype was squamous cell carcinoma (79.5%) followed byadenocarcinoma (16.4%).According to FIGO staging system, 31 (43.8%) of thepatients were diagnosed as stage 1-2 and 42 (56.2%) were as stage 3-4.Themedian PFS and OS are 44 months and 78 months. The 5-year survival rate is37.5% (12%-75%). Although there was no difference in length of life betweenhistological subtypes, both PFS and OS were longer in patients with good ECOGperformance score (0-1), early FIGO stage (1-2), tumor size <4 cm, and withoutparametrial and lymph node involvement. Multivariate analysis showed that ECOGperformance score, parametrial involvement and lymph node involvement wereindependent prognostic factors for PFS and OS.Conclusion: The stage at time ofdiagnosis of CC patients in our region is more advanced and their 5-yearsurvival rates are below the world average, so our women need to be betterinformed about this subject.
KW  - Cervical Cancer
KW  - HPV DNA
KW  - Prognostic factors
N2  - Amaç: Servikal kanser (SK) tüm dünyada kadınlarda kanserebağlı ölümlerin en sık 4. Sebebi iken ülkemizde 12. Sebebidir. En önemlietyolojik neden HPV olması nedeniyle tarama programları ile erken tanı ile kürolma şansı yüksek olan tümörlerdendir. Ancak ülkemizde SK’lerin uzun dönemyaşam verileri ile ilgili bilgiler kısıtlıdır. Bizde çalışmamızda öncelikliolarak SK tanılı hastalarımızın yaşam sürelerini ve bu süreleri predikte edenfaktörleri ortaya koymak istedik.Materyal ve metod: Erzurum Atatürk Üniversitesi Tıp Fakültesi TıbbiOnkoloji Anabilim Dalı'nda 2007-2017 yılları arasında SK nedeniyle takip edilen70 hasta çalışmaya retrospektif olarakdahil edildi. Genel sağkalım (OS) veprogresyonsuz sağkalım (PFS) ile klinikopatolojik parametreler arasındaki ilişkilerKaplan-Meier eğrileri kullanılarak analiz edildi ve log-rank testi ile karşılaştırıldı.Tek ve çok değişkenli analiz kriterlerin PFS ve OS için prognostik önemlerinitespit etmek için kullanılmıştır.Bulgular: Hastaların median yaşı 56’dır.En sık görülen histolojik alttip skuamoz hücreli karsinom (%79,5) ardındanadenokarsinom (%16,4) gelmektedir. FIGO evreleme sistemine göre hastaların 31’i(%43,8) evre 1-2, 42’si (%56,2) evre 3-4 olarak tanı almıştır. Median PFS ve OS44 ay ve 78 aydır. 5 yıllık yaşam oranı %37,5 (%12-%75) dur. Histolojikalttiplerin yaşam süreleri arasında fark olmamakla beraber ECOG performansskoru iyi (0-1) olanların, erken FIGO evresi (1-2) olanların, tumor boyutu<4 cm olanların, parametrial ve lenf nodu tutulumu olmayanların hem PFS hemde OS leri daha uzundur. Multivariate analizler sonucunda ECOG performansskoru, parametrial tutulum ve lenf nodu tutulumu PFS ve OS için bağımsızprognostik faktör olduğu tespit edilmiştir.Sonuç: Bölgemizdeki SK’lihastaların tanı anında evreleri daha ileri ve 5 yıllık yaşam oranları dünyaortalamalarının altındandır bu sebeple kadınlarımızın bu konuda daha iyibilinçlendirilmeleri gerekmektedir
CR  - 1.	Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393(10167):169-182
CR  - 2.	Aydoğdu MGS, Özsoy Ü. Cervical cancer and HPV. Androl Bul 2018;20:25−29
CR  - 3.	Crosbie EJ, Einstein HM, Franceschi S, Kitchener CH. Human papillomavirus and cervical cancer. Lancet. 2013;382(9895):889-99
CR  - 4.	Zhao H, He Y, Yang S, Zhao Q, Wu YM. Neoadjuvant chemotherapy with radical surgery vs radical surgery alone for cervical cancer: a systematic review and meta-analysis. Onco Targets Ther. 2019;12:1881–1891
CR  - 5.	Noone AM, Howlader N, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018
CR  - 6.	Hsu HC, Li X, Curtin JP, Goldberg JD, Schiff PB. Surveillance Epidemiology and End Results Analysis Demonstrates Improvement in Overall Survival for Cervical Cancer Patients Treated in the Era of Concurrent Chemoradiotherapy. Front Oncol. 2015; 5: 81.
CR  - 7.	Brisson M, Drolet M. Global elimination of cervical cancer as a public health problem. Lancet Oncol. 2019;20(3):319-321
CR  - 8.	Park KJ, Soslow RA. Current concepts in cervical pathology. Arch Pathol Lab Med. 2009;133(5): 729-738.
CR  - 9.	Gien LT, Beauchemin MC, Thomas G. Adenocarcinoma: a unique cervical cancer. Gynecologic oncology, 2010;116(1): 140-146.
CR  - 10.	Nakanishi T, Ishikawa H, Suzuki Y, et al. A comparison of prognoses of pathologic stage Ib adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2000;79:289–293.
CR  - 11.	Galic V, Herzog TJ, Lewin SN, et al. Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol 2012;125:287–291.
CR  - 12.	McIntyre JB, Wu JS, Craighead PS, et al. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol 2012;128:409–414.
CR  - 13.	Takekuma M, Kasamatsu Y, Kado N, et al. The issues regarding postoperative adjuvant therapy and prognostic risk factors for patients with stage I–II cervical cancer: A review. J Obstet Gynaecol Res. 2017;43(4): 617-626.
CR  - 14.	Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1990;38(3): 352-357.
CR  - 15.	Endo D, Todo Y, Okamoto K, Minobe S, Kato H, Nishiyama N. Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort. J Gynecol Oncol. 2015;26(1): 12-18.
CR  - 16.	Park JW, Bae JW. Prognostic significance of positive lymph node number in early cervical cancer. Mol Clin Oncol. 2016;4(6): 1052-1056.
CR  - 17.	Shinohara S, Ochi T, Miyazaki T, et al. Histopathological prognostic factors in patients with cervical cancer treated with radical hysterectomy and postoperative radiotherapy. Int J Clin Oncol. 2004;9(6): 503-509.
CR  - 18.	Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med.  2007;357(16):1579–1588.
CR  - 19.	Gultekin M, Zayifoglu Karaca M, Kucukyildiz I, et al. Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women. Int J Cancer. 2018;142(9):1952-1958.
UR  - https://doi.org/10.5798/dicletip.579312
L1  - https://dergipark.org.tr/tr/download/article-file/893246
ER  -